Sinotau is pleased to announce that the results of the Phase III clinical trial in China for our self-developed radionuclide therapeutic drug, ¹⁷⁷Lu-Dotatate(XTR008), have been officially published in the prestigious international oncology journal Annals of Oncology (Impact Factor: 65.4). Concurrently, the latest analysis results from this study were successfully selected as a Late-Breaking Abstract (LBA) for this […]
Recently, the Cardiovascular Imaging Professional Committee of the National Expert Committee on Cardiovascular Diseases was officially established. Initiated by experts including Academician Hu Shengshou and with Academician Wang Zhenchang serving as its first Chairman, the committee brings together hundreds of top experts in the field of cardiovascular imaging in China. Its establishment marks a new stage […]
The Annual Congress of the European Association of Nuclear Medicine (EANM), a top-tier academic conference in the global nuclear medicine field, will take place at the International Conference Centre in Barcelona, Spain on October 4-8, 2025. Focusing on cutting-edge topics in nuclear medicine, the EANM Congress is renowned for setting international clinical practice standards, and the guidelines it […]
Beijing, China —Beijing Sinotau International Pharmaceutical Technology Co. , Ltd. is pleased to announce that the innovative radiopharmaceutical XTR020 for prostate cancer diagnosis has recently completed the enrollment and dosing of all subjects in its Phase III clinical study in China, marking a significant milestone in the product’s research and development in China. Despite clear and […]
October 17-21, 2025– The European Society for Medical Oncology (ESMO) Congress, Europe’s most influential oncology conference, will be held in Berlin, Germany. The full results of the China Phase III registration clinical trial for Sinotau’s self-developed innovative radioconjugate (RDC) drug, XTR008, have been successfully selected as a Late-Breaking Abstract (LBA) and will be globally presented […]
BEIJING, China – September 8, 2025 – Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (“Sinotau”) is proud to announce that the Phase I, first-in-human study of self-developed innovative radiopharmaceutical XTR004, were awarded the Best Translational Paper Award – Molecular Imaging Category by the Journal of Nuclear Cardiology at the 30th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology (ASNC […]
Recently, Meilleur, a joint venture of Sinotau, that holds global rights to NAV-4694, an ß amyloid PET imaging agent for Alzheimer’s disease, was acquired by Lantheus. Recently published updated guidelines developed by a working group of the National Institute on Aging and the Alzheimer’s Association (NIA-AA) state that Alzheimer’s disease should be defined biologically, using protein-based biomarkers. These guidelines recommend that […]
First Amyloid PET Tracer Received Regulatory Approval in China
Beijing, China, October 17, 2023– the Press Conference on the Regulatory Approval of Florbetaben F 18 Injection, organized by Sinotau Pharmaceutical Group, the leading company of innovative radiopharmaceuticals in China, was successfully held in Beijing. Co-President Mrs. Yanmin Tang, Vice President and Secretary of the Board of Directors Mr. Wenbin Yu, Medical Marketing Director Mr.Xin Wang and other senior leaders of the company […]
BEIJING, China, 17 October 2023 – Sinotau Pharmaceutical Group and the British molecular imaging company Blue Earth Diagnostics Ltd are announcing an exclusive strategic agreement for the development, production, and commercialization of the innovative PSMA-targeted PET imaging agent flotufolastat (18F) in China. Flotufolastat (18F) is an optimized positron emission tomography (PET) imaging agent designed to target prostate-specific membrane antigen (PSMA) positive lesions, indicated […]
BEIJING, China, 21-23 September 2023 – The 2023 Academic Annual Meeting of the Chinese Society of Nuclear Medicine was successfully held in the ancient capital Xi’an, where experts and scholars in nuclear medicine and related fields, excellent companies and industry elites gathered together. As a leading company of innovative radiopharmaceuticals, Sinotau also participated in this event. The conference was organized […]
Beijing, China, 15 September, 2023 – Sinotau’s radiopharmaceutical product Florbetaben F-18 (with Chinese trade name 欧韦宁®) received regulatory approval from National Medical Products Administration (NMPA) in China. Florbetaben F 18 injection is a radiotracer used for PET scanning of the brain, which can be used for the diagnosis, differential diagnosis and therapeutic evaluation of AD by determining […]